BlueCrest Capital Management’s Pacific Biosciences PACB Stock Holding History

BlueCrest Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-23,400	Closed	-$271K	–	292
2023 Q1	$271K	Buy	+23,400	New	+$233K	0.01%	230
2019 Q4	–	Sell	-75,740	Closed	-$391K	–	529
2019 Q3	$391K	Buy	+75,740	New	+$424K	0.03%	312
2018 Q4	–	Sell	-18,398	Closed	-$100K	–	1274
2018 Q3	$100K	Buy	+18,398	New	+$78.9K	﹤0.01%	1385
2017 Q3	–	Sell	-43,585	Closed	-$155K	–	1030
2017 Q2	$155K	Buy	+43,585	New	+$176K	0.01%	783

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlueCrest Capital Management's PACB Position: Q2 2023 in Review

BlueCrest Capital Management sold out of Pacific Biosciences (PACB) in Q2 2023, closing a stake of 23,400 shares — an estimated $271K sold.

BlueCrest Capital Management first reported a position in PACB in Q2 2017 and held it in 4 quarters. The position peaked at $391K in Q3 2019. 271 funds tracked by Wall St. Rank hold PACB as of Q2 2023.

BlueCrest Capital Management reported no remaining Pacific Biosciences position as of Q2 2023 after selling out during the quarter.
BlueCrest Capital Management sold 23,400 Pacific Biosciences shares in Q2 2023, an estimated $271K.
BlueCrest Capital Management first reported a position in Pacific Biosciences in Q2 2017 and held it in 4 quarters.
BlueCrest Capital Management's Pacific Biosciences position peaked at $391K in Q3 2019.
271 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2023.

Based on BlueCrest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.